Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.62 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.62 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.62 |
| ▸ | CHRNB3 | Q05901 | 3/20 | 0.62 |
| ▸ | CHRNA6 | Q15825 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658219 | 1.00 | HPGD (0.95) | HPGDALDH1A1TSHRHTTCHRNB2 | |
| SCHEMBL19612780 | 0.97 | HPGD (1.00) | HPGDALDH1A1TSHRHTTCHRNB2 | |
| SCHEMBL3504308 | 0.97 | HPGD (1.00) | HPGDALDH1A1TSHRHTTCHRNB2 | |
| SCHEMBL20186941 | 0.97 | HPGD (1.00) | HPGDALDH1A1TSHRHTTCHRNB2 | |
| SCHEMBL16992039 | 0.97 | HPGD (1.00) | HPGDALDH1A1TSHRHTTCHRNB2 | |
| SCHEMBL18228450 | 0.97 | HPGD (1.00) | HPGDALDH1A1TSHRHTTCHRNB2 | |
| SCHEMBL28185998 | 0.94 | — | — | |
| SCHEMBL3703489 | 0.92 | ALDH1A1 (0.81) | HPGDALDH1A1TSHRHTTCHRNB2 | |
| SCHEMBL1117898 | 0.92 | HPGD (0.81) | HPGDALDH1A1TSHRHTTCHRNB2 | |
| SCHEMBL2946268 | 0.91 | HPGD (0.78) | HPGDALDH1A1TSHRHTTCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390340-A1 | PYRROLIDINE KRAS INHIBITORS | INCYTE CORP (US) | 2024-11-28 | — | — | US | disclosed |
| US-10689368-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-23 | — | — | US | disclosed |
| US-20190337925-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2019-11-07 | — | — | US | disclosed |
| US-10385039-B2 | Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-08-20 | — | — | US | disclosed |
| CN-109776374-A | The pyrrolidine derivative and application thereof that acyl group replaces | 广东东阳光药业有限公司 | 2019-05-21 | — | — | CN | disclosed |
| US-20190112294-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARNIC M1 RECEPTOR AND/OR M4 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2019-04-18 | — | — | US | disclosed |
| US-10196380-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-02-05 | — | — | US | disclosed |
| US-20180179184-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| US-9926297-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-03-27 | — | — | US | disclosed |
| EP-2920172-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | Merck Sharp & Dohme Corp. (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2015095011-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-25 | — | — | WO | disclosed |
| WO-2014075393-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014075392-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2012096928-A2 | PYRIMIDINONE DERIVATIVES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-07-19 | — | — | WO | disclosed |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2012037299-A2 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| EP-1758883-B1 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORP (US) | 2011-11-02 | — | — | EP | disclosed |
| WO-2011082077-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2005116009-A1 | SUBSTITUTED 2-QUINOLYL-OXAZOLES USEFUL AS PDE4 INHIBITORS | SCHERING CORPORATION (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | NAMPT, NNMT, NME2 | HPGD 132/4885ALDH1A1 2689/4885TSHR 2661/4885 |
| US-10196380-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | HPGD 3379/4885ALDH1A1 1421/4885TSHR 65/4885 |
| US-20240390340-A1 | PYRROLIDINE KRAS INHIBITORS | KRAS, NRAS, HRAS | HPGD 448/4885ALDH1A1 1931/4885TSHR 4532/4885 |
| US-20190112294-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARNIC M1 RECEPTOR AND/OR M4 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | HPGD 4168/4885ALDH1A1 1173/4885TSHR 64/4885 |
| US-10689368-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor | CHRM1, CHRM2, CHRM4 | HPGD 3377/4885ALDH1A1 1306/4885TSHR 64/4885 |
| US-10385039-B2 | Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists | CHRM1, CHRM2, CHRM5 | HPGD 4168/4885ALDH1A1 1173/4885TSHR 64/4885 |
| US-20190337925-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | CHRM1, CHRM2, CHRM4 | HPGD 3377/4885ALDH1A1 1306/4885TSHR 64/4885 |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | BRCA1, NQO2, NQO1 | HPGD 87/4885ALDH1A1 1674/4885TSHR 4313/4885 |
| US-20180179184-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | HPGD 3379/4885ALDH1A1 1421/4885TSHR 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.